Cargando…

Contrast-enhanced CT findings-based model to predict MVI in patients with hepatocellular carcinoma

BACKGROUND: Microvascular invasion (MVI) is important in early recurrence and leads to poor overall survival (OS) in hepatocellular carcinoma (HCC). A number of studies have reported independent risk factors for MVI. In this retrospective study, we designed to develop a preoperative model for predic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Qi, Zhou, Zheyu, Zhang, Xudong, Xu, Xiaoliang, Liu, Yang, Wang, Kun, Liu, Qiaoyu, Wang, Jincheng, Zhao, Yu, Yin, Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798548/
https://www.ncbi.nlm.nih.gov/pubmed/36577952
http://dx.doi.org/10.1186/s12876-022-02586-2
_version_ 1784860927613468672
author Yue, Qi
Zhou, Zheyu
Zhang, Xudong
Xu, Xiaoliang
Liu, Yang
Wang, Kun
Liu, Qiaoyu
Wang, Jincheng
Zhao, Yu
Yin, Yin
author_facet Yue, Qi
Zhou, Zheyu
Zhang, Xudong
Xu, Xiaoliang
Liu, Yang
Wang, Kun
Liu, Qiaoyu
Wang, Jincheng
Zhao, Yu
Yin, Yin
author_sort Yue, Qi
collection PubMed
description BACKGROUND: Microvascular invasion (MVI) is important in early recurrence and leads to poor overall survival (OS) in hepatocellular carcinoma (HCC). A number of studies have reported independent risk factors for MVI. In this retrospective study, we designed to develop a preoperative model for predicting the presence of MVI in HCC patients to help surgeons in their surgical decision-making and improve patient management. PATIENTS AND METHODS: We developed a predictive model based on a nomogram in a training cohort of 225 HCC patients. We analyzed patients’ clinical information, laboratory examinations, and imaging features from contrast-enhanced CT. Mann–Whitney U test and multiple logistic regression analysis were used to confirm independent risk factors and develop the predictive model. Internal and external validation was performed on 75 and 77 HCC patients, respectively. Moreover, the diagnostic performance of our model was evaluated using receiver operating characteristic (ROC) curves. RESULTS: In the training cohort, maximum tumor diameter (> 50 mm), tumor margin, direct bilirubin (> 2.7 µmol/L), and AFP (> 360.7 ng/mL) were confirmed as independent risk factors for MVI. In the internal and external validation cohort, the developed nomogram model demonstrated good diagnostic ability for MVI with an area under the curve (AUC) of 0.723 and 0.829, respectively. CONCLUSION: Based on routine clinical examinations, which may be helpful for clinical decision-making, we have developed a nomogram model that can successfully assess the risk of MVI in HCC patients preoperatively. When predicting HCC patients with a high risk of MVI, the surgeons may perform an anatomical or wide-margin hepatectomy on the patient.
format Online
Article
Text
id pubmed-9798548
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97985482022-12-30 Contrast-enhanced CT findings-based model to predict MVI in patients with hepatocellular carcinoma Yue, Qi Zhou, Zheyu Zhang, Xudong Xu, Xiaoliang Liu, Yang Wang, Kun Liu, Qiaoyu Wang, Jincheng Zhao, Yu Yin, Yin BMC Gastroenterol Research BACKGROUND: Microvascular invasion (MVI) is important in early recurrence and leads to poor overall survival (OS) in hepatocellular carcinoma (HCC). A number of studies have reported independent risk factors for MVI. In this retrospective study, we designed to develop a preoperative model for predicting the presence of MVI in HCC patients to help surgeons in their surgical decision-making and improve patient management. PATIENTS AND METHODS: We developed a predictive model based on a nomogram in a training cohort of 225 HCC patients. We analyzed patients’ clinical information, laboratory examinations, and imaging features from contrast-enhanced CT. Mann–Whitney U test and multiple logistic regression analysis were used to confirm independent risk factors and develop the predictive model. Internal and external validation was performed on 75 and 77 HCC patients, respectively. Moreover, the diagnostic performance of our model was evaluated using receiver operating characteristic (ROC) curves. RESULTS: In the training cohort, maximum tumor diameter (> 50 mm), tumor margin, direct bilirubin (> 2.7 µmol/L), and AFP (> 360.7 ng/mL) were confirmed as independent risk factors for MVI. In the internal and external validation cohort, the developed nomogram model demonstrated good diagnostic ability for MVI with an area under the curve (AUC) of 0.723 and 0.829, respectively. CONCLUSION: Based on routine clinical examinations, which may be helpful for clinical decision-making, we have developed a nomogram model that can successfully assess the risk of MVI in HCC patients preoperatively. When predicting HCC patients with a high risk of MVI, the surgeons may perform an anatomical or wide-margin hepatectomy on the patient. BioMed Central 2022-12-28 /pmc/articles/PMC9798548/ /pubmed/36577952 http://dx.doi.org/10.1186/s12876-022-02586-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yue, Qi
Zhou, Zheyu
Zhang, Xudong
Xu, Xiaoliang
Liu, Yang
Wang, Kun
Liu, Qiaoyu
Wang, Jincheng
Zhao, Yu
Yin, Yin
Contrast-enhanced CT findings-based model to predict MVI in patients with hepatocellular carcinoma
title Contrast-enhanced CT findings-based model to predict MVI in patients with hepatocellular carcinoma
title_full Contrast-enhanced CT findings-based model to predict MVI in patients with hepatocellular carcinoma
title_fullStr Contrast-enhanced CT findings-based model to predict MVI in patients with hepatocellular carcinoma
title_full_unstemmed Contrast-enhanced CT findings-based model to predict MVI in patients with hepatocellular carcinoma
title_short Contrast-enhanced CT findings-based model to predict MVI in patients with hepatocellular carcinoma
title_sort contrast-enhanced ct findings-based model to predict mvi in patients with hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798548/
https://www.ncbi.nlm.nih.gov/pubmed/36577952
http://dx.doi.org/10.1186/s12876-022-02586-2
work_keys_str_mv AT yueqi contrastenhancedctfindingsbasedmodeltopredictmviinpatientswithhepatocellularcarcinoma
AT zhouzheyu contrastenhancedctfindingsbasedmodeltopredictmviinpatientswithhepatocellularcarcinoma
AT zhangxudong contrastenhancedctfindingsbasedmodeltopredictmviinpatientswithhepatocellularcarcinoma
AT xuxiaoliang contrastenhancedctfindingsbasedmodeltopredictmviinpatientswithhepatocellularcarcinoma
AT liuyang contrastenhancedctfindingsbasedmodeltopredictmviinpatientswithhepatocellularcarcinoma
AT wangkun contrastenhancedctfindingsbasedmodeltopredictmviinpatientswithhepatocellularcarcinoma
AT liuqiaoyu contrastenhancedctfindingsbasedmodeltopredictmviinpatientswithhepatocellularcarcinoma
AT wangjincheng contrastenhancedctfindingsbasedmodeltopredictmviinpatientswithhepatocellularcarcinoma
AT zhaoyu contrastenhancedctfindingsbasedmodeltopredictmviinpatientswithhepatocellularcarcinoma
AT yinyin contrastenhancedctfindingsbasedmodeltopredictmviinpatientswithhepatocellularcarcinoma